The feasibility study of transdermal drug delivery systems for antidepressants possessing hydrophilicity or hydrophobicity

다국어 초록 (Multilingual Abstract)

The feasibility studies on the transdermal drug delivery systems have been performed to avoid the systemic side-effects and gastric disorders that could be occurred due to the transient high blood concentration after oral administration of antidepressants such as venlafaxine HCl and citalopram. When surfactants of tween 80® and plasticizer of diethyl phthalate were combined with citalopram–ethylene vinyl acetate (EVA) matrix, the permeation of citalopram showed the best enhancement. As well as, venlafaxine HCl gels were prepared using carbomer, oleic acid and/or propylene glycol to enhance the skin permeation of venlafaxine HCl. The citalopram-EVA matrix containing tween 80® and diethyl phthalate as permeation enhancers might be a good transdermal delivery system for providing sustained plasma concentrations of citalopram. Also, venlafaxine HCl showed the possibility to be enhanced skin permeation in the formulation of gels with carbomer including penetration enhancer, oleic acid and/or propylene glycol.

참고문헌 (Reference)

1 Wilson AD, "Venlafaxine ingestion isassociated with rhabdomyolysis in adults: a case series" 32 : 97-101, 2007

2 Sampson SM, "Treating depression with selective serotoninreuptake inhibitors: a practical approach" 76 : 739-744, 2001

3 Troy SM, "Thepharmacokinetics of venlafaxine when given in a twice dailyregimen" 35 : 404-409, 1995

4 Singh G, "Screeningof venlafaxine hydrochloride for transdermal delivery: passivediffusion and iontophoresis" 9 : 791-797, 2008

5 Kent JM, "SNaRIs, NaSSAs, and NaRIs: new agents for thetreatment of depression" 355 : 911-918, 2000

6 Stahl SM, "SNRIs: theirpharmacology, clinical efficacy and tolerability in comparisonwith other classes of antidepressants" 10 : 732-747, 2005

7 Wille SM, "Relevantissues in the monitoring and the toxicology of antidepressants" 45 : 25-89, 2008

8 Kilts CD, "Potential new drug delivery system for antidepressants:an overview" 64 : 31-33, 2003

9 Hiemke C, "Pharmacokinetics of selective serotoninreuptake inhibitors" 85 : 11-28, 2000

10 Kognan A, "Microemulsions as transdermal drugdelivery vehicles" 123 : 369-385, 2006

11 Sweetman SC, "Martindale: the complete drug reference, 34thedn" PhP Pharmaceutical 321-323, 2005

12 Pacher P, "Current trends inthe development of new antidepressants" 8 : 89-100, 2001

13 Bezchlibnyk-Butler K, "Citalopram—areview of pharmacological and clinical effects" 25 : 241-256, 2000

14 Uges DRA, "ADs and antipsychotics, In Forensic science" Elsevier 229-256, 2000